Study
Luteolin and glycitein from Codonopsis pilosula ameliorate age-related locomotor decline in C. elegans via DAF-16-dependent but autophagy-divergent pathways
Luteolin and glycitein improved locomotor measures in aged C. elegans through DAF-16/FOXO, with different autophagy requirements.
Summary Can compounds from a plant help older worms move better? Show / hide ↓
Researchers tested three substances from Codonopsis pilosula, a medicinal plant, in aged C. elegans, tiny worms often used in aging studies. No people participated. Luteolin and glycitein improved bending and swimming-like movements and seemed to reduce damage to muscles and mitochondria, the cell parts that make energy. Both activated DAF-16, a gene-control protein linked to stress protection, and blocking it removed the benefit. Luteolin also needed lgg-1, a gene involved in autophagy, the cell’s recycling system, while glycitein did not; a third substance changed recycling structures but did not improve movement.
What this means for you: This is early evidence from worms, not proof that these substances improve movement, aging, or health in people. You can ignore this when deciding what supplements to buy because the study gives no human evidence or clinical recommendation.
early evidenceYan Zhuang and colleagues tested three compounds isolated from Codonopsis pilosula in aged Caenorhabditis elegans. Luteolin and glycitein improved body-bend and thrashing frequencies. Both compounds reduced abnormalities in muscle structure and mitochondrial morphology. Both promoted nuclear translocation of DAF-16/FOXO. Knockdown of daf-16 abolished the locomotor benefit. The pathways then diverged. Luteolin required an lgg-1-dependent autophagy-related process. Glycitein improved locomotion without relying on the autophagic pathway. Alpha-spinasterol changed autophagosome levels but did not improve locomotor capacity. The PubMed record does not state N, doses, treatment duration, effect sizes, p values, or confidence intervals. The model is a nematode. The compounds were not tested in humans, and the study does not show improved lifespan or human healthspan. DAF-16 is a useful FOXO-related mechanism, but pathway activity in a nematode is not evidence that a supplement reproduces the effect in people. The result is a mechanistic lead. It does not support a clinical recommendation for luteolin, glycitein, or Codonopsis pilosula.
These findings elucidate the distinct pharmacological mechanisms of Codonopsis pilosula constituents, highlighting their potential as modulators of healthspan via DAF-16-dependent but mechanistically distinct pathways.
N, dose, duration, effect sizes, and statistical details are unavailable in the PubMed record. C. elegans findings require independent replication and mammalian or human validation.